Leukemia

Latest News

Dark blue line illustration on a light blue background of two prescription bottles next to two pills

FDA Fast Track Designation Given to AUTX-703 in Relapsed/Refractory AML

By Ashley Chan

February 26th 2025

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

By Darlene Dobkowski, MA

February 3rd 2025

green background with blue text indicating FDA and green text indicating approved with a green checkmark

FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS

By Bridget Hoyt

January 24th 2025

yellow background with a white outline indicating blood cells

Obe-Cel Induces Durable Remissions in Adult Relapsed/Refractory B-Cell ALL

By Chris Ryan

January 18th 2025

Revumenib Combo Yields High Remission Rates in Relapsed/Refractory AML

By Darlene Dobkowski, MA

December 23rd 2024

More News

CAR T-Cell Therapy Continues to Revolutionize Hematologic Cancer Treatment

Lindsay Fischer

August 31st 2021

Kelly Garvin, BSN, RN, OCN, discusses the impact of CAR T-cell therapy on patients and how nurses care for them, as well as her expectations on how indications will grow.

Ponatinib Approved by FDA for Resistant or Intolerant Chronic-Phase CML

Kristi Rosa

December 19th 2020

The FDA has approved ponatinib for the treatment of patients with chronic-phase chronic myeloid leukemia that is resistant or intolerant to at least 2 prior kinase inhibitors.

Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers

Lauren M. Green

April 30th 2015

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

<1 2 3